Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875902 | 1.00 | MEN1 (0.52) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL22279886 | 0.81 | MEN1 (0.49) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL20875995 | 0.81 | MEN1 (0.49) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL20875996 | 0.81 | MEN1 (0.49) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL20875914 | 0.81 | MEN1 (0.52) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL22279815 | 0.79 | MEN1 (0.53) | MEN1KMT2ASIGMAR1PKMSIRT2 | |
| SCHEMBL22262834 | 0.73 | SIGMAR1 (0.48) | MEN1KMT2ASIGMAR1SIRT2SIRT1 | |
| SCHEMBL29136262 | 0.73 | GRM2 (0.50) | MEN1KMT2ASIGMAR1GRM2GSK3B | |
| SCHEMBL28949764 | 0.73 | HPGD (0.74) | MEN1KMT2AGSK3B | |
| SCHEMBL9803156 | 0.72 | HPGD (0.43) | MEN1KMT2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| EP-3692035-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| WO-2019068841-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | MEN1 4027/4885KMT2A 4046/4885SIGMAR1 2247/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | MEN1 4027/4885KMT2A 4046/4885SIGMAR1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.